Skip to content
    UTHR
    Earnings call· Mar 2026(Q1 FY26)

    UNITED THERAPEUTICS Q1 FY26 earnings call UTHR

    May 6, 2026 Source

    Executive summary

    United Therapeutics Q1 FY26 — Pipeline Success Drives Significant Future Revenue Growth

    United Therapeutics reported a strong quarter driven by significant advancements in its pipeline, particularly with ralinepag for PAH and Tyvaso for IPF, which are poised to become best-in-class therapies. The company is aggressively pursuing multiple formulations and indications, including a newly unveiled ralinepag DPI, to expand market reach and expects substantial revenue growth in the coming years. Despite some Q1 headwinds from seasonality and weather, underlying demand metrics for existing products show positive trends, positioning the company for sustained double-digit long-term growth.

    Highlights

    5

    • Ralinepag demonstrated a threefold reduction in disease progression for PAH patients in the OUTCOME study, with potential to double PAH patients to over 30,000.

    • Tyvaso for IPF showed improved forced vital capacity by over 100 milliliters of oxygen, exceeding existing drugs.

    • The company anticipates a revenue run rate of $4 billion by the end of 2027, with ralinepag and Tyvaso for IPF expected to double this figure.

    • Tyvaso DPI contributed 9% year-over-year growth to total Tyvaso revenue of $458 million.

    • Referrals for Tyvaso are at pre-competitor launch levels, and patient shipments have grown for the last 5 months.

    Concerns

    2

    • Q1 FY26 total revenue of $782 million was impacted by typical historical seasonality trends, severe winter weather, and pharmacy operations issues.

    • Sales of nebulized Tyvaso lagged during the quarter due to external factors.

    Guidance & targets

    7
    CategoryTargetConfidence
    Revenue run rate
    $4 billion
    high materiality
    High
    Revenue run rate (post-approval)
    More than double $4 billion
    high materiality
    High
    PAH patient count (post-ralinepag launch)
    Over 30,000
    high materiality
    High
    Tyvaso for IPF sNDA filing
    By the end of the summer
    high materiality
    High
    Tyvaso for IPF launch
    By Q2 of next year
    high materiality
    Medium
    Ralinepag launch
    Mid next year
    high materiality
    Medium
    Ralinepag DPI Phase I study completion
    Before the end of the year
    medium materiality
    High

    Operational metrics

    8
    Total revenue
    $782 million
    Q1 FY26

    Total revenue reported for the first quarter of 2026.

    Tyvaso revenue
    $458 million
    Q1 FY26

    Total Tyvaso revenue for the first quarter of 2026.

    Tyvaso DPI growth
    9%year-over-year
    Q1 FY26

    Tyvaso DPI contributed 9% year-over-year growth, driven by increased patient demand.

    Tyvaso referrals/prescriptions
    Approximately the same levelpre-[indiscernible] launch
    Q1 FY26 exit

    Tyvaso referrals or prescriptions rates are at approximately the same level they were before a competitor launched.

    Tyvaso patient shipments
    Grown
    Last 5 months

    Patient shipments for Tyvaso have grown for the last 5 months.

    Tyvaso DPI higher dose graduation
    Steady increase
    Ongoing

    A steady increase in patients graduating to higher doses of Tyvaso DPI with the launch of new capsule and kit combinations.

    Sales force investments deployment
    Deployed
    Middle of this year

    Sales force investments in anticipation of ralinepag and IPF approvals will be deployed in the middle of this year to expand reach and capture market share.

    Ralinepag DPI formulation
    —
    Ongoing

    The ralinepag DPI will leverage MannKind's crystal carrier IP, similar to Tyvaso DPI, and will not be a prodrug, initially using the ralinepag molecule investigated for solid dose.

    Industry KPIs

    8
    MetricValueDetails
    Launch access metrics—
    Pipeline read out calendarTETON 1 and TETON 2 trials completed; OUTCOME study completed; Ralinepag DPI Phase I study completion before end of year; PH-COPD Phase I ongoing, Phase II/III planned
    Product franchise net sales$458 millionUSD
    Regulatory approvals filingsTyvaso for IPF sNDA filing by end of summer; Ralinepag FDA approval expected mid next year
    Peak long term sales guidance$4 billionUSD
    Prescription volume new startsApproximately the same level
    Clinical trial efficacy safety dataThreefold reduction in disease progression; FVC improved over 100 mL
    Cumulative patients uptake since launchOver 30,000patients

    Product announcements

    1
    ProductTypeDetails
    Ralinepag DPIlaunch

    Deals & partnerships

    1
    MannKindExclusive option for a second DPI

    United Therapeutics activated its exclusive option with MannKind for a second DPI, which is now identified as ralinepag DPI. This partnership leverages MannKind's crystal carrier IP for the new inhaled formulation.

    Risks & headwinds

    3
    Historical seasonality and external factors impacting salesQ1 FY26

    Impacted Q1 FY26 total revenue of $782 million and nebulized Tyvaso sales

    Mitigation: Expect to return to sequential growth in the near term; issues have since been rectified.

    Pharmacy operations issuesQ1 FY26

    Slowed starts during Q1 FY26, particularly in February

    Mitigation: Issues have since been rectified.

    Severe winter weatherQ1 FY26

    Impacted Q1 FY26 sales

    Mitigation: Weather is a transient factor; no specific mitigation mentioned beyond general expectation of recovery.

    What to watch in Q2 FY26

    4

    Tyvaso for IPF sNDA filing

    Next quarter
    CurrentExpected by end of summer
    TargetFiling submitted

    Why it matters

    Successful and timely filing is a key step towards market approval and realizing significant revenue potential for IPF.

    We look forward to filing a supplemental new drug application by the end of the summer and believe the highly compelling body of evidence across both the TETON studies could warrant an expedited approval through priority review to bring this therapy to those patients in need as quickly as possible.

    Q&A highlights

    6

    What is the bridging strategy for Tyvaso DPI in IPF, and will it be available at launch? How does Tyvaso compare to other new IPF therapies like Esbriet?

    The company is working with the FDA on a bridging strategy for Tyvaso DPI in IPF, likely involving healthy volunteer PK comparability and patient safety/efficacy studies. They agree there's significant pent-up demand for new IPF therapies, and Tyvaso is expected to be used either first-line or in combination with other treatments, similar to PAH.

    “I mean, I guess the short answer is, we agree with you, and that's really kind of how we're starting to think about potential launch curve. We're starting to have conversations with physicians now.”

    asked by Ashwani Verma · answered by Leigh Peterson

    2 min read6 chapters

    Detailed Narrative

    01

    Transformative Pipeline Success with Ralinepag and Tyvaso for IPF

    United Therapeutics highlighted unprecedented🌐 clinical success with two key therapeutics: ralinepag for Pulmonary Arterial Hypertension (PAH) and Tyvaso for Idiopathic Pulmonary Fibrosis (IPF). The OUTCOME study for ralinepag demonstrated a threefold reduction in disease progression compared to background therapy, with superior hazard ratios and durability. For IPF, the TETON trials showed Tyvaso significantly improved forced vital capacity (FVC) by over 100 milliliters of oxygen, surpassing existing treatments. These results position both drugs as potentially best-in-class in their respective large indications.

    02

    Significant Revenue Growth Projections

    The company projects its current revenue run rate of $3 billion will increase to $4 billion by the end of 2027. Management expressed high confidence that, once approved, ralinepag and Tyvaso for IPF will collectively double this $4 billion run rate. Specifically, ralinepag is expected to double the number of PAH patients treated by the company to over 30,000 within two years of its launch, underscoring the substantial market opportunity for these pipeline assets.

    03

    Introduction of Ralinepag DPI and Expanded Formulations

    United Therapeutics announced the emergence of an inhaled formulation of ralinepag, named 'ralinepag DPI,' from its 'Skunk Works' division. This new product leverages MannKind's crystal carrier IP, similar to Tyvaso DPI, and is expected to be a once-daily product. The company is pursuing multiple formulations for Tyvaso in IPF (DPI, SMI) and ralinepag (oral, DPI, SMI) to cater to diverse patient needs and maximize market penetration, reflecting a 'multiple shots on goal' strategy.

    04

    Commercial Strategy and Market Positioning

    The commercial strategy focuses on expanding reach in PH-ILD and PAH with existing products while preparing for the launches of ralinepag and Tyvaso for IPF. Sales force investments are being deployed mid-year to support these efforts. Management believes the strong performance of new therapies in IPF by competitors indicates significant pent-up demand, and Tyvaso is expected to be used either first-line or in combination therapy, similar to the PAH market.

    05

    Regulatory and Development Timelines

    The supplemental New Drug Application (sNDA) for Tyvaso in IPF is expected to be filed by the end of summer 2026, with a potential launch by Q2 FY27 under a standard review timeline. Oral ralinepag is anticipated to launch mid-FY27, also assuming a smooth FDA approval. For ralinepag DPI, a Phase I study is expected to be completed before the end of 2026, with rapid progression to efficacy studies for PAH, PH-ILD, IPF, and PPF, with PAH expected to be the first approval.

    06

    PH-COPD Program Advancement

    The company provided an update on its PH-COPD program, which will utilize treprostinil SMI. A Phase I study in healthy volunteers is ongoing, with a Phase II study planned for PH-COPD patients, followed by a Phase III study. The development considers learnings from previous years regarding patient populations and aims for an enriched patient population eligibility criteria.

    AI-generated summary of the company’s earnings call. Not investment advice.